Positive topline results of Apnimed's LunAIRo trial put AD109 on track for approval as the first oral sleep apnoea medication.

ANI Pharmaceuticals has disclosed the outcomes of its NEW DAY trial, assessing Iluvien 0.19mg, in people with diabetic macular oedema.

Abivax's obefazimod resulted in an average 16.4% placebo-adjusted clinical remission rate in UC patients across the two trials.

The trail demonstrates that a swallowable, low-pill, non-absorbed iron polymer can match or exceed sevelamer in phosphate control.

Windward Bio has launched the Phase II POLARIS trial of the recombinant, fully human monoclonal antibody, WIN378, in individuals with asthma.

Combining Scancell's melanoma drug iSCIB1+ with Yervoy and Opdivo significantly improved patient overall response rate.

Arch Biopartners has initiated subject recruitment in its Phase II study aimed at assessing cilastatin in preventing AKI.

Diakonos Oncology has dosed the first subject in its Phase II trial of DOC1021 for treating glioblastoma (GBM).

AstraZeneca's Tagrisso combined with pemetrexed and platinum-based chemotherapy has shown improvement in overall survival (OS).

Monte Rosa Therapeutics has dosed the first participants in the Phase I trial of the NEK7-directed molecular glue degrader (MGD), MRT-8102.

The first patient has been treated with InterVene’s Recana thrombectomy system for restoring patency (blood flow) in chronically obstructed deep veins and venous stents.

Roche’s IgG2 monoclonal antibody (mAb) astegolimab has yielded mixed results in chronic obstructive pulmonary disease (COPD), succeeding in a Phase IIb trial but failing in a Phase III study.